Multimodality Treatment of Pancreatic Cancer With Liver Metastases Using Chemotherapy, Radiation Therapy, and/or Chinese Herbal Medicine

被引:46
作者
Ouyang, Huaqiang [1 ,2 ]
Wang, Peng [1 ,2 ]
Meng, Zhiqiang [1 ,2 ]
Chen, Zhen [1 ,2 ]
Yu, Er'xin [1 ,2 ]
Jin, Huan [3 ]
Chang, David Z. [4 ]
Liao, Zhongxing [5 ]
Cohen, Lorenzo [6 ,7 ,8 ]
Liu, Luming [1 ,2 ]
机构
[1] Fudan Univ, Dept Integrat Oncol, Canc Hosp, Shanghai 200032, Peoples R China
[2] Canc Hosp, Comprehens Treatment Grp Hepatobiliary & Pancreat, Shanghai, Peoples R China
[3] Fudan Univ, Dept Biostat & Social Med, Sch Publ Hlth, Shanghai 200032, Peoples R China
[4] Univ Texas MD Anderson Canc Ctr, Dept Gastrointestinal Med Oncol, Houston, TX 77030 USA
[5] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Integrat Med Program, Houston, TX 77030 USA
[7] Univ Texas MD Anderson Canc Ctr, Dept Behav Sci, Houston, TX 77030 USA
[8] Univ Texas MD Anderson Canc Ctr, Dept Gen Oncol, Houston, TX 77030 USA
关键词
pancreatic cancer; liver metastases; multimodality treatment; prognosis; HEPATIC ARTERIAL INFUSION; PROGNOSTIC-FACTORS; SURVIVAL; GEMCITABINE; ADENOCARCINOMA; CARCINOMA; RESECTION; 5-FLUOROURACIL; FEASIBILITY; TRIAL;
D O I
10.1097/MPA.0b013e3181e6e398
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Objective: To explore the utility of multidisciplinary approaches in the treatment of patients with pancreatic cancer with liver metastases (PCLM). Methods: From 2002 to 2007, a total of 164 consecutive patients with PCLM treated with chemotherapy, radiation therapy, and/or Chinese herbal medicine were included in this study. Clinical parameters, treatments received, and survival time from initial diagnosis were analyzed. Results: Of the 164 patients, 113 (69%) were men and 51 (31%) were women, with median age of 58 years. One hundred thirty-two patients (80%) had synchronous liver metastases, and 57 patients (35%) had extrahepatic metastases. Overall median survival time of the 164 patients was 4.7 months; 23 (14%) were alive at least 12 months after initial diagnosis of liver metastases. Karnofsky performance status of less than 80, weight loss (>10% within 6 months), ascites, and carbohydrate antigen 19-9 of 1000 U/mL or greater were the most relevant predictors of poor survival. Multivariate analysis showed that chemotherapy and Chinese herbal medicine were protective factors. Conclusions: Multimodality treatment is well tolerated by patients with PCLM and may be effective in prolonging their survival. Awareness of the implications of these prognostic factors may assist in evaluating the survival potential of patients and selecting the most appropriate treatments.
引用
收藏
页码:120 / 125
页数:6
相关论文
共 38 条
[21]  
Kindler HL, 2007, J CLIN ONCOL, V25, DOI 10.1200/JCO.2007.12.0949
[22]   Phase II trial of bevacizurnab plus gemcitabine in patients with advanced pancreatic cancer [J].
Kindler, HL ;
Friberg, G ;
Singh, DA ;
Locker, G ;
Nattam, S ;
Kozloff, M ;
Taber, DA ;
Karrison, T ;
Dachman, A ;
Stadler, WM ;
Vokes, EE .
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (31) :8033-8040
[23]   Prognostic factors in patients with unresectable locally advanced pancreatic adenocarcinoma treated with chemoradiation [J].
Krishnan, Sunil ;
Rana, Vishal ;
Janjan, Nora A. ;
Abbruzzese, James L. ;
Gould, Morris S. ;
Das, Prajnan ;
Delclos, Marc E. ;
Palla, Shana ;
Guha, Sushovan ;
Varadhachary, Gauri ;
Evans, Douglas B. ;
Wolff, Robert A. ;
Crane, Christopher H. .
CANCER, 2006, 107 (11) :2589-2596
[24]   Prognostic factors and prognostic index for chemonaive and gemcitabine-refractory patients with advanced pancreatic cancer [J].
Marechal, R. ;
Demols, A. ;
Gay, F. ;
De Maertelaere, V. ;
Arvanitaki, M. ;
Hendlisz, A. ;
Van Laethem, J. L. .
ONCOLOGY, 2007, 73 (1-2) :41-51
[25]   A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer [J].
Morizane, Chigusa ;
Okusaka, Takuji ;
Furuse, Junji ;
Ishii, Hiroshi ;
Ueno, Hideki ;
Ikeda, Masafumi ;
Nakachi, Kohei ;
Najima, Mina ;
Ogura, Takashi ;
Suzuki, Eiichiro .
CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2009, 63 (02) :313-319
[26]   Factors influencing survival after bypass procedures in patients with advanced pancreatic adenocarcinomas [J].
Mueller, Michael W. ;
Friess, Helmut ;
Koeninger, Joerg ;
Martin, David ;
Wente, Moritz N. ;
Hinz, Ulf ;
Ceyhan, Gueralp O. ;
Blaha, Pavel ;
Kleeff, Joerg ;
Buechler, Markus W. .
AMERICAN JOURNAL OF SURGERY, 2008, 195 (02) :221-228
[27]   CHEMOTHERAPY PROLONGS SURVIVAL IN INOPERABLE PANCREATIC-CARCINOMA [J].
PALMER, KR ;
KERR, M ;
KNOWLES, G ;
CULL, A ;
CARTER, DC ;
LEONARD, RCF .
BRITISH JOURNAL OF SURGERY, 1994, 81 (06) :882-885
[28]   Survival and prognostic factors of unresectable pancreatic cancer [J].
Park, Joo Kyung ;
Yoon, Yong Bum ;
Kim, Yong-Tae ;
Ryu, Ji Kon ;
Yoon, Won Jae ;
Lee, Sang Hyub .
JOURNAL OF CLINICAL GASTROENTEROLOGY, 2008, 42 (01) :86-91
[29]   Estimating the world cancer burden: GLOBOCAN 2000 [J].
Parkin, DM ;
Bray, F ;
Ferlay, J ;
Pisani, P .
INTERNATIONAL JOURNAL OF CANCER, 2001, 94 (02) :153-156
[30]   Feasibility of a randomized trial of extended lymphadenectomy for pancreatic cancer [J].
Pawlik, TM ;
Abdalla, EK ;
Barnett, CC ;
Ahmad, SA ;
Cleary, KR ;
Vauthey, JN ;
Lee, JE ;
Evans, DB ;
Pisters, PWT .
ARCHIVES OF SURGERY, 2005, 140 (06) :584-589